Cargando…

DNA damage repair gene mutations predict the efficacy of platinum-based chemotherapy and immunotherapy plus platinum-based chemotherapy in advanced non-small cell lung cancer: a retrospective Chinese cohort study

BACKGROUND: Platinum-based chemotherapy (PC) and immunotherapy plus platinum-based chemotherapy (IPC) remain the first-line treatment for advanced NSCLC. But only a minority patients benefit from PC, and existing biomarkers, such as PD-L1, have been shown to be defective in predicting the efficacy o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Zhiwei, Sun, Lingling, Zheng, Yating, Chen, Hanrui, Zheng, Xinting, Luo, Jiamin, Gu, Chuying, Lin, Ruiting, Huang, Mengli, Bai, Yuezong, Chen, Zhe-Sheng, Kinslow, Connor J., Loh, Jerold, Lin, Lizhu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830265/ https://www.ncbi.nlm.nih.gov/pubmed/36636408 http://dx.doi.org/10.21037/tlcr-22-746

Ejemplares similares

Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma
por: Zhu, Yunshu, et al.
Publicado: (2020)

Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
por: Grande, Enrique, et al.
Publicado: (2023)

IMpower132: Atezolizumab plus platinum‐based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients
por: Nishio, Makoto, et al.
Publicado: (2021)

Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
por: Zhai, Xiaoyu, et al.
Publicado: (2017)

Safety and feasibility of fasting in combination with platinum-based chemotherapy
por: Dorff, Tanya B., et al.
Publicado: (2016)

Genetic Polymorphisms and the Efficacy of Platinum-Based Chemotherapy: Review
por: Afifah, Nadiya Nurul, et al.
Publicado: (2020)

Pembrolizumab plus platinum-based chemotherapy for unfavorable cancer of unknown primary site: Case report
por: Kamada, Teppei, et al.
Publicado: (2020)

Zhengyuan capsules for the treatment of chemotherapy-induced cancer-related fatigue in stage IIIB–IV unresectable NSCLC: study protocol for a randomized, multi-center, double-blind, placebo-controlled clinical trial
por: Lin, Jietao, et al.
Publicado: (2022)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy
por: Molassiotis, Alex, et al.
Publicado: (2019)

Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis
por: Liu, Xiaoyan, et al.
Publicado: (2022)

Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management
por: Oronsky, Bryan, et al.
Publicado: (2017)

Looking beyond the audiogram in ototoxicity associated with platinum-based chemotherapy
por: Baguley, David M., et al.
Publicado: (2019)

Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer
por: Yang, Ling, et al.
Publicado: (2022)

Platinum‐based chemotherapy for early triple‐negative breast cancer
por: Mason, Sofia RE, et al.
Publicado: (2023)

Platinum-Based Versus Non-Platinum-Based Chemotherapy as First Line Treatment of Inoperable, Advanced Gastric Adenocarcinoma: A Meta-Analysis
por: Chen, Wei-Wei, et al.
Publicado: (2013)

Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
por: Zhang, Jian, et al.
Publicado: (2015)

Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

WISP1 Polymorphisms Contribute to Platinum-Based Chemotherapy Toxicity in Lung Cancer Patients
por: Chen, Juan, et al.
Publicado: (2014)

Prediction of response and adverse drug reaction of pemetrexed plus platinum-based chemotherapy in lung adenocarcinoma by serum metabolomic profiling
por: Gong, Wei-Jing, et al.
Publicado: (2022)

Network Pharmacology/Metabolomics-Based Validation of AMPK and PI3K/AKT Signaling Pathway as a Central Role of Shengqi Fuzheng Injection Regulation of Mitochondrial Dysfunction in Cancer-Related Fatigue
por: Guo, Wei, et al.
Publicado: (2021)

Dissecting the single-cell transcriptome network in patients with esophageal squamous cell carcinoma receiving operative paclitaxel plus platinum chemotherapy
por: Chen, Zhencong, et al.
Publicado: (2021)

Rapid palliation of symptoms with platinum-based chemotherapy plus cetuximab in recurrent oral cancer: a case report
por: Mesía, Ricard, et al.
Publicado: (2010)

Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study
por: Salimon, Maëva, et al.
Publicado: (2018)

Pembrolizumab plus platinum-based chemotherapy for squamous non-small cell lung cancer: the new kid on the block
por: Hockenhull, Kimberley, et al.
Publicado: (2021)

An ultrasound-activatable platinum prodrug for sono-sensitized chemotherapy
por: Liu, Gongyuan, et al.
Publicado: (2023)

Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002)

Nanocarriers containing platinum compounds for combination chemotherapy
por: Fang, Guihua, et al.
Publicado: (2022)

Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysis
por: Chen, Juan, et al.
Publicado: (2016)

Association of variations in the CAT and prognosis in lung cancer patients with platinum-based chemotherapy
por: Liu, Jia-Si, et al.
Publicado: (2023)

Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival
por: Jernigan, Amelia M., et al.
Publicado: (2013)

Diversifying the platinum-based chemotherapy toolkit for immunogenic cancer cell death
por: Garg, Abhishek D., et al.
Publicado: (2020)

Effect of XPC polymorphisms on the response to platinum-based chemotherapy: a meta-analysis
por: Xie, Chenyao, et al.
Publicado: (2019)

The Efficacy and Response Predictors of Platinum-Based Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer
por: Huang, Yuhui, et al.
Publicado: (2020)

Precise prediction of the sensitivity of platinum chemotherapy in SCLC: Establishing and verifying the feasibility of a CT-based radiomics nomogram
por: Su, Yanping, et al.
Publicado: (2023)

Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer
por: Hu, Weiheng, et al.
Publicado: (2016)

The power of immunotherapy plus platinum–based chemotherapy for locally advanced or early stage non-small cell lung cancer
por: Hofman, Paul
Publicado: (2020)

Gemcitabine Plus Vinorelbine as Second-Line Therapy in Patients With Metastatic Esophageal Cancer Previously Treated With Platinum-Based Chemotherapy
por: Wang, Yue-shen, et al.
Publicado: (2016)

Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy
por: Hung, Hsing-Wei, et al.
Publicado: (2021)

Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis
por: Wang, Chang-Jun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j6cqfufc902i2s4naevl4kuhcf